THE LIVER DISEASE AND DILI NEWSLETTER  by Melissa Palmer, MD —  Featuring Developments in Drug-Induced Liver Disease and All Areas of Liver Disease

The Liver Disease and DILI Newsletter  is Now Live!

All content is personally written by world-renowned liver disease and drug-induced liver injury consultant Melissa Palmer, MD  

Medical Monitoring for Liver Drug Trial Safety

Medical monitoring is essential to trial safety, yet the role remains inconsistently defined across the industry. A recent LinkedIn poll of clinical research professionals showed strong support for creating a formal certification framework. With trial complexity rising, the conversation about medical monitoring is becoming increasingly important.
Below is a brief article summarizing the poll results and outlining what a practical, risk‑based framework could look like.
To discuss medical monitoring standards, reach out at info@medsurgpi.com.
Many thanks to all those who worked on this article: Roger Morgan, MD FACS; Melissa Palmer, M.D.; Freddy Byrth; Patrick F. Loebs, MSW, MPH, CPC; Emilia J.; Katie-Louise Dawson MD MPH